Skip to main content

Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics

  • Giacomo Grassi (a1), Lorenzo Poli (a1), Andrea Cantisani (a1), Lorenzo Righi (a2), Gabriella Ferrari (a1) and Stefano Pallanti (a1)...

The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs.


We therefore recruited 60 schizophrenic patients treated with clozapine or other AAPs. We assessed the prevalence rates of OCD or OC symptoms and hypochondriasis or hypochondriac symptoms in the whole group of patients and in clozapine-treated patients versus patients treated with other AAPs.


Schizophrenic patients had a higher comorbidity rate of OCD (26.6% vs 1–3%) and hypochondriasis (20% vs 1%) than the general population. These comorbidities were more frequent in schizophrenic patients treated with clozapine versus patients treated with other AAPs (36.7% vs 16.7% and 33.3% vs 6.7%). Clozapine-treated patients showed a higher mean Y-BOCS and HY-BOCS score when compared to patients treated with other AAPs (10.90 vs 5.90, p = .099; 15.40 vs 8.93, p = .166). A statistical significant correlation was found between the Y-BOCS and HY-BOCS scores of the whole group (r = .378, p = 0.03). Furthermore, we found an inverse correlation between the global level of functioning and the diagnosis of hypochondriasis (p = .048) and the severity of hypochondriac symptoms (p = .047).


Hypochondriasis could represent an important clinical feature of schizophrenic patients treated with atypical antipsychotics, and further research is needed in this field.

Corresponding author
*Address for correspondence: Giacomo Grassi, MD, Department of Neuroscience, University of Florence, AOU Careggi, Via delle Gore 2H, 50134, Florence, Italy. (Email:
Hide All
1.Achim, AM, Maziade, M, Raymond, E, etal. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011; 37(4): 811821.
2.Tranulis, C, Potvin, S, Gourgue, M, etal. The paradox of quetiapine in obsessive-compulsive disorder. CNS Spectr. 2005; 10(5): 356361.
3.Schirmbeck, F, Zink, M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol. 2012; 10(1): 8895.
4.Cunill, R, Castells, X, Simeon, D. Relationship between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2009; 70(1): 7082.
5.Mukhopadhaya, K, Krishnaiah, R, Taye, T, etal. Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause of clinical concern. J Psychopharmacol. 2009; 23(1): 613.
6.Sterk, B, Lankreijer, K, Linszen, DH, de Haan, L. Obsessive-compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis: onset and relationship to psychotic symptoms. Aust N Z J Psychiatry. 2011; 45(5): 400405.
7.Zink, M, Knopf, U, Kuwilsky, A. Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia. Aust N Z J Psychiatry. 2007; 41(3): 293294.
8.Lim, M, Park, DY, Kwon, JS, Joo, YH, Hong, KS. Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics. J Clin Psychopharmacol. 2007; 27(6): 712713.
9.deHaan, L, Sterk, B, Wouters, L, Linszen, DH. The 5-years course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull. 2013; 39(1): 151160.
10.Hwang, MY, Kim, SW, Yum, SY, Opler, LA. Management of schizophrenia with obsessive-compulsive features. Psychiatr Clin North Am. 2009; 32(4): 835851.
11.Lykouras, L, Alevizos, B, Michalopoulou, P, Rabavilas, A. Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(3): 333346.
12.Alevizos, B, Papageorgiou, C, Christodoulou, GN. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol. 2004; 7(3): 375377.
13.Ke, CL, Yen, CF, Chen, CC, etal. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. Kaohsiung J Med Sci. 2004; 20(6): 295301.
14.Ozer, S, Arsava, M, Ertugrul, A, Demir, B. Obsessive compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(4): 724727.
15.Stamouli, S, Lykouras, L. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol. 2006; 26(4): 396400.
16.Baker, RW, Chengappa, KN, Baird, JW, etal. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992; 53(12): 439442.
17.deHaan, L, Linszen, DH, Gorsira, R. Clozapine and obsessions in patients with recent onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 1999; 60(6): 364365.
18.Ertugrul, A, Anil Yagcioglu, AE, Eni, N, Yazici, KM. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci. 2005; 59(2): 219222.
19.Mahendra, R, Liew, E, Subramaniam, M. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry. 2007; 68(4): 542545.
20.Sa, AR, Hounie, AG, Sampaio, AS, etal. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr Psychiatry. 2009; 50(5): 437442.
21.deHaan, L, Oekeneva, A, Van Amelsvoort, T, Linszen, D. Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders. Eur Psychiatry. 2004; 19(8): 524.
22.Poyurovsky, M, Weizman, A, Weizman, R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004; 18(14): 9891010.
23.Schirmbeck, F, Esslinger, C, Rausch, F, etal. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med. 2011; 41(11): 23612373.
24.Schirmbeck, F, Rausch, F, Englisch, S, etal. Differential effects of antipsychotics agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. J Psychopharmacol. 2013; 27(4): 349357.
25.Tanahashi, S, Yamamura, S, Nakagawa, M, Motomura, E, Okada, M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol. 2012; 165(5): 15431555.
26.Pallanti, S, Grassi, G, Cantisani, A. Approaches to treatment resistance. In: Zohar J, ed. Obsessive-Compulsive Disorder: Current Science and Clinical Practice. Hoboken, NJ: John Wiley & Sons; 2012; 99134.
27.Kwon, JS, Joo, YH, Nam, HJ, etal. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry. 2009; 66(11): 12331241.
28.Schirmbeck, F, Nieratschker, V, Frank, J, etal. Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents. Psychiatr Genet. 2012; 22(5): 245252.
29.Cai, J, Zhang, W, Yi, Z, etal. Influence of polymorphism in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology (Berl). 230(1): 4955.
30.Poyurovsky, M, Fuchs, C, Faragian, S, etal. Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder. Can J Psychiatry. 2006; 51(12): 746754.
31.Bienvenu, OJ, Samuels, JF, Wuliek, LA, etal. Is obsessive-compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective. Psychol Med. 2012; 42(1): 113.
32.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
33.First, MB, Spritzer, RL, Gibbon, M, Willians, JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Patient Edition (Version 2.0). Biometric Research Department. New York: New York State Psychiatric Institute; 1995.
34.Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261276.
35.Montogomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382389.
36.Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1): 5055.
37.Goodman, W, Price, L, Rasmussen, S, etal. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), part I: development, use, and reliability. Arch Gen Psychiatry. 1989; 46: 10061011.
38.Goodman, W, Price, L, Rasmussen, S, etal. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), part II: validity. Arch Gen Psychiatry. 1989; 46(11): 10121016.
39.Greeven, A, Spinhoven, P, van Balkom, AJ. Hypochondriasis Y-BOCS: a study of the psychometric properties of a clinician-administered semi-structured interview to assess hypochondriacal thoughts and behaviours. Clin Psychol Psychother. 2009; 16(5): 431443.
40.Hall, RC. Global assessment of functioning: a modified scale. Psychosomatics. 1995; 36(3): 267275.
41.Starcevic, V. Hypochondriasis and health anxiety: conceptual challenges. Br J Psychiatry. 2013; 202(1): 78.
42.Hiller, W, Fichter, MM. High utilizers of medical care: a crucial subgroup among somatizing patients. J Psychosom Res. 2004; 56(4): 437443.
43.deHaan, L, Beuk, N, Hoogenboom, B, Dingemans, P, Linszen, D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002; 63(2): 104107.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 3
Total number of PDF views: 57 *
Loading metrics...

Abstract views

Total abstract views: 479 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 26th September 2018. This data will be updated every 24 hours.